FAO-OIE-AU/IBAR-IAEA
Consultative Group Meeting on CBPP in Africa
Towards sustainable CBPP control programmes for Africa
(Rome, 12 - 14 November 2003)
CBPP Control Strategies
Strategic control of CBPP should be progressive and based on impact assessments and cost benefit analyses done with appropriate methods including participatory techniques to cover regional, national and zonal levels.
PANVAC and the production of CBPP vaccine should be internationally accredited.
Research into antibiotic treatments, vaccines and their targeted delivery and diagnostic tools should continue.
Pilot projects to assess the effectiveness of antibiotic treatments and elective vaccination should be conducted.
CBPP should be a model for the improvement of veterinary services and public/private partnerships.
Mathematical modelling should be used in CBPP research.
Adequate funding should be available to control CBPP in sub-Saharan Africa.
Tools for CBPP Control - Vaccines
PANVAC should assume a central role in the research and improvement of vaccine production, formulation and its proper reconstitution.
AU/IBAR should financially empower PANVAC to enable compliance to OIE and other manufacturing principles for vaccine production and certification.
Research into the improvement of vaccines should continue and include the possibility of differentiation between vaccinated and non-vaccinated animals.
OIE and FAO should be sent a list of CBPP vaccine producers and performances as established by PANVAC.
Tools for CBPP Control - Use of Antibiotics and Diagnostic Tests
Daignostic Tests
The prevalence of CBPP should be established by serological surveillance.
Serological, clinical and pathological investigations should be performed to confirm the absence of CBPP.
New outbreaks should be confirmed by the isolation and identification of Mycoplasma mycoides subspecies mycoides small colony variant (MmmSC), because currently available serological tests are inadequate for individual diagnosis.
Research must be conducted to establish the effects of antibiotic treatment and multiple vaccinations on CBPP.
Robust penside tests must be developed including those based on the detection of CPS antigens.
Standardised reagents and quality control sera should be introduced by FAO/IAEA into Africa for the CFT.
Immunoblotting test should be considered during the critical phases of CBPP control programmes.
Serological tests that differentiate vaccinated from non-vaccinated animals should be developed.
The general quality assurance scheme for CBPP diagnostic reagents should be devised by FAO/IAEA.
Antibiotics
Pilot trials: PACE and FAO should instigate pilot trials to assess the effectiveness in the field in Africa of antibiotics and chemotherapeutic agents against CBPP.
Studies on Microbial Sensitivity: The VLA should be requested to carry out in vitro studies to establish the MIC of relevant antibiotics to African Mmm SC strains.
Studies on the Safety and Impact of Antibiotics on the Consumer: Systems to monitor antibiotic residues in meat and recommendations for antibiotic use in animal productions systems should be followed.
